Data/hora: 02/06/2024 09:07:35

Provedor de dados: | 55
País: | Brazil
Título: | Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate
Autores: | Caramelli,Bruno; Bernoche,Claudia Y.S.M. de; Sartori,Ana M. C.; Sposito,Andrei C.; Santos,Raul D.; Monachini,Maristela C.; Strabelli,Tania; Uip,Davi.
Data: | 2001-12-01
Ano: | 2001
Palavras-chave: | Cholesterol; Lipids; HIV infection; Triglycerides.
Resumo: | Hyperlipidemia has been frequently recorded as a side effect of treating HIV patients with protease inhibitors (PI). This study was initiated to analyze the modifications on blood lipids in HIV-patients receiving PI and the safety and efficacy of the treatment with fenofibrate. Total (TC) and HDL-cholesterol, triglycerides (TG), and CD4+ T-cell counts were measured in 30 HAART-naive patients (Group I) before and after PI introduction. In a second phase of the study, the effects of fenofibrate on lipids, CPK, CD4+, and viral load were determined in 13 patients (Group II) with elevated TC or TG. In Group I, 60% of the patients showed TC or TG elevations. Average increments of 31% and 146% in TC and TG respectively (p&lt;0.0006 and p&lt;0.0001) were observed. In Group II, fenofibrate treatment was associated with decrements of 6.6% (TC) and 45.7% (TG) (p=0.07 and 0.0002) and no modifications on CPK, CD4+, and viral load. In conclusion, hyperlipidemia is common during the treatment of HIV with protease inhibitors, and fenofibrate appears to be an effective and safe choice for its treatment.
Tipo: | Info:eu-repo/semantics/article
Idioma: | Inglês
Identificador: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702001000600007
Editor: | Brazilian Society of Infectious Diseases
Relação: | 10.1590/S1413-86702001000600007
Formato: | text/html
Fonte: | Brazilian Journal of Infectious Diseases  v.5 n.6 2001
Fonte: | info:eu-repo/semantics/openAccess